Alberto Pinzon Ardila, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by UCB, Inc. at 44.5% of the total. Among epilepsy clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,398 payments — averaging $102.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$64K
- SK Life Science, Inc.$41K
- Livanova USA, Inc.$8K
- Jazz Pharmaceuticals Inc.$5K
- AbbVie$4K
- UCB SA$3K
- plus $19K from 54 others
Across 94 payments — averaging $2201.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$91K
- Sunovion Pharmaceuticals Inc.$74K
- Jazz Pharmaceuticals Inc.$33K
- GW Research Limited$9K
What the payments were for
- Consulting fees$10,5967%
- Speaking & faculty fees$77,58154%
- Travel & lodging$15,99711%
- Food & beverage$39,47327%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$35,842
- Briviact$35,207
- Nayzilam$14,606
- Fintepla$7,921
- VNS Therapy$6,495
- Cenobamate$2,618
- INFINITY$1,778
- Epidiolex$1,655
- VNS - Sentiva$1,121
- UBRELVY$625
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$411
- QULIPTA$370
- REXULTI$369
- Mavenclad$352
- BOTOX$250
- ULTOMIRIS$245
- QUVIVIQ$244
- Inspire$172
- Exablate$139
- NURTEC ODT$125
How this compares
$143,771 in reported general payments places this provider in the 90th percentile of 23 epilepsy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 168 | $858,773 |
| FinteplaFenfluramine Hcl | 15 | $238,053 |
| AptiomEslicarbazepine Acetate | 60 | $137,840 |
| OnfiClobazam | 19 | $98,461 |
| BriviactBrivaracetam | 40 | $73,166 |
| NayzilamMidazolam | 51 | $56,635 |
| SympazanClobazam | 12 | $45,879 |
| XcopriCenobamate | 26 | $44,191 |
| Rufinamide | 32 | $22,968 |
| Lacosamide | 132 | $22,606 |
| Nurtec OdtRimegepant Sulfate | 13 | $14,827 |
| Levetiracetam | 249 | $11,650 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $11,002 |
| Clobazam | 98 | $9,701 |
| Diazepam | 35 | $7,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact, Nayzilam | $63,995 | $367,854106 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $259 | $137,84060 claims |
| Lundbeck LLCOnfi | $471 | $98,46119 claims |
| Aquestive Therapeutics, Inc.Sympazan | $129 | $45,87912 claims |
| SK Life Science, Inc.Xcopri | $40,527 | $44,19126 claims |
| PfizerNurtec Odt, Dilantin | $483 | $18,14531 claims |
| Upsher-smith Laboratories LLCTopiramate | $54 | $1,78794 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $132 | $66113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 23 epilepsy providers in Florida.
Other epilepsy in Miami
- Andrew LermanMiami$249K
- Miguel Melo-BicchiMiami$15K
- Carlos MillanMiami$7K
- Luis TornesMiami$6K
- Gisela Moreira EyngMiami$3K
- Brian CostellBoca Raton$469K
- Jaivir RathoreOrlando$38K
- Dipali NemadeOrlando$38K
- Mohamed NasserWeston$28K
- William TatumJacksonville$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.